Therapeutic potential of drugs to modulate DNA repair in cancer

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 6, 2007, Pages 783-799

  Curtin, Nicola ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cancer; DNA protein kinase; DNA repair; O6 alkylguanine DNA alkyltransferase; Poly(ADP ribose) polymerase

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 AMINOBENZAMIDE; 6 O BENZYLGUANINE; 6 O METHYLGUANINE; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; ABT 888; AG 014699; AG 14361; ALKYLATING AGENT; AZD 2281; BENZIMIDAZOLE DERIVATIVE; BS 201; CAMPTOTHECIN; CARMUSTINE; CEP 6800; CHLORMETHINE; DACARBAZINE; GPI 15427; INDOLE DERIVATIVE; INO 1001; IRINOTECAN; LOMEGUATRIB; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NU 1085; PD 128763; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; ASTROCYTOMA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN TUMOR; BREAST CANCER; CANCER RELAPSE; CANCER THERAPY; CARCINOGENESIS; CHEMOSENSITIZATION; CLINICAL TRIAL; COLON CANCER; CYTOTOXICITY; DISORDERS OF DNA SYNTHESIS AND REPAIR; DNA REPAIR; DNA STRAND BREAKAGE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SCREENING; EXCISION REPAIR; GAMMA IRRADIATION; GENETIC STABILITY; GLIOMA; HUMAN; LEUKEMIA; LYMPHOMA; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE CYCLE TREATMENT; MYELOMA; NONHUMAN; OPTIMAL DRUG DOSE; RADIOSENSITIZATION; RECOMMENDED DRUG DOSE; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; T CELL LYMPHOMA; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA REPAIR; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 34250377983     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.6.783     Document Type: Review

References (117)

1. HUTCHINSON F: Chemical changes induced in DNA by ionising radiation. In: Progress in Nucleic Acid Research and Molecular Biology (1985) 32:115-154.
2. HOEIJMAKERS JH: Genome maintenance mechanisms for preventing cancer. Nature (2001) 411:366-374.
3. BARTKOVA J, HOREJSI Z, KOED K et al.: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature (2005) 434:864-870.
4. JACKSON AL AND LOEB LA: The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat. Res. (2001) 477:7-21.
5. VENKITARAMAN AR: Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell (2002) 108:171-182.
6. BRONNER CE, BAKER SM, MORRISON PT et al.: Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature (1994) 368:258-261
7. + and methylation-tolerant mismatch repair compromised cells: facts and models. Mutat. Res. (1997) 381:227-241.
8. TUTT A, BERTWISTLE D, VALENTINE J et al.: Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J. (2001) 20:4704-4716.
9. 6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy. Curr. Opin. Pharmacol. (2006) 6:355-363.
10. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. (1990) 50:6119-6129.
11. AYI TC, LOH KC, ALI RB, LI BF: Intracellular localization of human DNA repair enzyme methylguanine-DNA methyltransferase by antibodies and its importance. Cancer Res. (1992) 52:6423-6430.
12. 6-methylguanine-DNA methyltransferase activity in human tumors. Carcinogenesis (1992) 13:1503-1507.
13. 6-alkylguanine-DNA alkyltransferase gene is elevated in human breast tumor cells. Anti-Cancer Res. (1997) 17:4311-4315.
14. 6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. J. Neurosurg. (1989) 70:573-577.
15. 6-methylguanine-DNA methyltransferase in cell survival, mutagenesis and carcinogenesis. Mutat. Res. (1985) 145:1-16.
16. ESTELLER M, GARCIA-FONCILLAS J, ANDION E et al.: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. (2000) 343:1350-1354.
17. 6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J. Clin. Oncol. (1998) 16:3310-3315.
18. 6-akylguanines. Cancer Res. (1985) 45(12 Pt. 1):6413-6417.
19. 6-methylguanine as a free base. Cancer Res. (1986) 46(4 Pt. 1): 1663-1668.
20. 6- methylguanine. Cancer Chemother. Pharmacol. (1989) 25(2):103-108.
21. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc. Natl. Acad. Sci. USA (1990) 87:5368-5372.
22. 6-benzylguanine: a comparative study in vitro. Br. J. Cancer (1996) 73:482-490.
23. 6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat. Rev. (2006) 32:261-276.
24. 6-alkylguanine-DNA alkyltransferase inactivation in cancer chemotherapy. Mini-Rev. Med. Chem. (2003) 3:471-485.
25. 6-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int. J. Cancer (2000) 85:248-252.
26. 6-benzylguanine for patients undergoing surgery for malignant glioma. J. Clin. Oncol. (1998) 16:3570-3575.
27. GERSON SL: MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer (2004) 4:296-307.
28. 6-alkylguanine-DNA-Alkytransferase: Phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. (2006) 12:1577-1584.
29. ROITT IM: The inhibition of carbohydrate metabolism in ascites-tumour cells by ethyleneimines. Biochem. J. (1956) 63:300-307.
30. CHAMBON P, WEILL JD, MANDEL P: Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem. Biophys. Res. Commun. (1963) 11:39-43.
31. DE MURCIA G, MENISSIER DE MURCIA J: Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem. Sci. (1994) 19:172-176.
32. SCHREIBER V, DANTZER F, AME JC, DE MURCIA G: Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. (2006) 7:517-528.
33. SCHREIBER V, AME J-C, DOLLE P et al.: Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision repair in association with PARP-1 and XRCC1. J. Biol. Chem. (2002) 277:23028-23036.
34. MENDOZA-ALVAREZ H, ALVAREZ-GONZALEZ R: Poly(ADP-ribose) polymerase is a catalytic dimer and the automodification reaction is intermolecular. J. Biol. Chem. (1993) 268:22575-22580.
35. POIRIER GG, DE MURCIA G, JONGSTRA-BILEN J, NIEDERGANG C, MANDEL P: Poly(ADP-ribosyl)ation of polynucleosomes causes relaxation of chromatin structure. Proc. Natl. Acad. Sci. USA (1982) 79:3423-3427.
36. REALINI CA, ALTHAUS FR: Histone shuttling by poly(ADP-ribosylation). J. Biol. Chem. (1992) 267:18858-18865.
37. EL-KHAMISY SF, MASUTANI M, SUZUKI H, CALDECOTT KW: A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res. (2003) 31:5526-5533.
38. MASSON M, NIEDERGANG C, SCHREIBER V, MULLER S, MENISSIER-DE MURCIA J, DE MURCIA G: XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol. Cell. Biol. (1998) 18:3563-3571.
39. CALDECOTT KW: XRCC1 and DNA strand break repair. DNA Repair (Amst.) (2003) 2:955-969.
40. DANTZER F, DE LA RUBIA G, MENISSIER-DE MURCIA J, HOSTOMSKY Z, DE MURCIA G, SCHREIBER V: Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. Biochemistry (2000) 39:7559-7569.
41. DANTZER F, SCHREIBER V, NIEDERGANG C et al.: Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie (1999) 81:69-75.
42. BENJAMIN R C, GILL D M: Poly(ADP-ribose) synthesis in vitro programmed by damaged DNA: comparison of DNA molecules containing different types of strand breaks. J. Biol. Chem. (1980) 255:10502-10508.
43. RUSCETTI T, LEHNERT BE, HALBROOK J et al.: Stimulation of the DNA-dependent protein kinase by poly(ADP-ribose) polymerase. J. Biol. Chem. (1998) 273:14461-14467.
44. AUDEBERT M, SALLES B, WEINFELD M, CALSOU P: Involvement of polynucleotide kinase in a poly(ADP-ribose) polymerase-1-dependent DNA double strand breaks rejoining pathway. J. Mol Biol. (2006) 356:257-265.
45. WANG M, WU W, WU W et al.: PARP-1 and Ku compete for repair of DNA double strand breaks by distinctive NHEJ pathway. Nucl. Acids Res. (2006) 34:6170-6182.
46. BOULTON S, KYLE S, DURKACZ BW: Interactive effects of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis (Lond) (1999) 20:199-203
47. VEUGER SJ, CURTIN NJ, RICHARDSON CJ, SMITH GC, DURKACZ BW: Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res. (2003) 63:6008-6015.
48. VEUGER SJ, CURTIN NJ, SMITH GC, DURKACZ BW: Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene (2004) 23:7322-7329.
49. PURNELL MR, WHISH WJ: Novel inhibitors of poly(ADP-ribose) synthetase. Biochem. J. (1980) 185:775-777.
50. DURKACZ BW, OMIDIJI O, GRAY DA, SHALL S: (ADP-ribose)n participates in DNA excision repair. Nature (1980) 283:593-596.
51. GRIFFIN RJ, PEMBERTON LC, RHODES D et al.: Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP). Anti-Cancer Drug Des. (1995) 10:507-514.
52. SUTO MJ, TURNER WR, ARUNDEL-SUTO CM, WERBEL LM, SEBOLT-LEOPOLD JS: Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase. Anti-Cancer Drug Des. (1991) 6:107-117.
53. BOWMAN KJ, NEWELL DR, CALVERT AH, CURTIN NJ: Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br. J. Cancer (2001) 84:106-112.
54. BANASIK M, KOMURA H, SHIMOYAMA M, UEDA K: Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J. Biol. Chem. (1992) 267:1569-1575.
55. DELANEY CA, WANG LZ, KYLE S et al.: Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin. Cancer Res. (2000) 6:2860-2867.
56. CURTIN NJ: PARP inhibitors for cancer therapy. Expert Rev. Mol. Med. (2005) 7:1-20.
57. JAGTAP P, SZABO C: Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov. (2005) 4:421-440.
58. TENTORI L, GRAZIANI G: Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol. Res. (2005) 52:25-33.
59. WOON EC, THREADGILL MD: Poly(ADP-ribose)polymerase inhibition - where now? Curr. Med. Chem. (2005) 12:2373-2392.
60. TENTORI L, PORTARENA I, GRAZIANI G: Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol. Res. (2002) 45:73-78.
61. BOULTON S, PEMBERTON LC, PORTEOUS JK et al.: Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br. J. Cancer (1995) 72:849-856.
62. TENTORI I, LEONETTI C, SCARSELLA M et al.: Systemic administration of GPI 15427: a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin. Cancer Res. (2003) 9:5370-5379.
63. LOH VM JR, COCKROFT X-L, DILLON KJ et al.: Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase. Bio-org. Med. Chem. Lett. (2005) 15:2235-2238.
64. COCKROFT X-L, DILLON KJ, DIXON L et al.: Phthalazinones 2: optimisation and synthesis of novel inhibitors of poly(ADP-ribose) polymerase. Bio-org. Med. Chem. Lett. (2006) 16:1040-1044.
65. MIKNYOCZKI SJ, JONES-BOLIN S, PRITCHARD S et al.: Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800:a poly(ADP-ribose) polymerase inhibitor. Mol. Cancer Ther. (2003) 2:371-382.
66. CALABRESE CR, ALMASSY R, BARTON S et al.: Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst. (2004) 96:56-67.
67. CALABRESE CR, BATEY MA, THOMAS HD et al.: Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin. Cancer Res. (2003) 9:2711-2718.
68. 6-benzylguanine for patients undergoing surgery for malignant glioma. J. Clin. Oncol. (1998) 16:3570-3575.
69. HERMAN JG, UMAR A, POLYAK K et al.: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA (1998) 95:6870-6875.
70. LIU L, TAVERNA P, WHITACRE CM et al.: Pharmacological disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin. Cancer Res. (1999) 5:2908-2917.
71. CURTIN NJ, WANG, L-Z, YIAKOUVAKI A et al.: Novel PARP-1 inhibitor, AG14361:restores sensitivity to temozolomide in mismatch repair deficient cells. Clin. Cancer Res. (2004) 10:881-889.
72. TENTORI L, LEONETTI C, SCARSELLA M et al.: Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J. (2006) 20:1709-1711.
73. CHENG CL, JOHNSON SP, KEIR ST et al.: Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol. Cancer Ther. (2005) 4:1364-1368.
74. YUNG TM, SATO S, SATOH MS: Poly(ADP-ribosyl)ation as a DNA damage-induced post-translational modification regulating poly(ADP-ribose) polymerase-1-topoisomerase I interaction. J. Biol. Chem. (2004) 279:39686-39696.
75. SMITH LM, WILLMORE E, AUSTIN CA, CURTIN NJ: The novel poly(ADP-Ribose) polymerase inhibitor, AG14361:sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin. Cancer Res. (2005) 11:8449-8457.
76. PLO I, LIAO ZY, BARCELO JM et al.: Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. DNA Repair (Amst.) (2003) 2:1087-1100.
77. MALANGA M, ALTHAUS FR: Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and Induces DNA strand break resealing. J. Biol. Chem. (2004) 279:5244-5248.
78. BEN-HUR E: Involvement of poly(ADP-ribose) in the radiation response of mammalian cells. Int. J. Radiat. Biol. (1984) 46:659-671.
79. ARUNDEL-SUTO CM, SCAVONE SV, TURNER WR et al.: Effects of PD128763:a new potent inhibitor of poly(ADP-ribose) polymerase, on X-ray induced cellular recovery processes in Chinese hamster V79 cells. Radiat. Res. (1991) 126:367-371.
80. BOWMAN K J, WHITE A, GOLDING BT et al.: Potentiation of anticancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors, NU1025 and NU1064. Br. J. Cancer (1998) 78:1269-1277.
81. VOGELSTEIN B, KINZLER KW: Cancer genes and the pathways they control. Nat. Med. (2004) 10:789-799.
82. OIKAWA A, TOHDA H, KANAI M, MIWA M, SUGIMURA T: Inhibitors of poly(adenosine diphosphate ribose) polymerase induce sister chromatid exchanges. Biochem. Biophys. Res. Commun. (1980) 97:1311-1316.
83. LINDAHL T, SATOH MS, POIRIER GG, KLUNGLAND A: Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks. Trends Biochem. Sci. (1995) 20:405-411.
84. SCHULTZ N, LOPEZ E, SALEH-GOHARI N, HELLEDAY T: Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res. (2003) 31:4959-4964.
85. BRYANT HE, SCHULTZ N, THOMAS HD et al.: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose)polymerase. Nature (2005) 434:913-917.
86. FARMER H, MCCABE N, LORD CJ et al.: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 434:917-921.
87. HARTWELL L P SZANKASI C ROBERTS A MURRAY, FRIEND S: Integrating generic approaches into the discovery of anticancer drugs. Science (1997) 278:1064-1068.
88. TURNER N, TUTT A, ASHWORTH A: Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer (2004) 4:814-819
89. MCCABE N, TURNER NC, LORD CJ et al.: Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. (2006) 66:8109-8115.
90. BRYANT HE, HELLEDAY T: Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Res. (2006) 34:1685-1691.
91. LORD CJ, GARRETT MD, ASHWORTH A: Targeting the double-strand DNA break repair pathway as a therapeutic strategy. Clin. Cancer Res. (2006) 12:4463-4468.
92. PLUMMER ER: Inhibition of poly(ADP-ribose) polymerase in cancer. Curr. Opin. Pharmacol. (2006) 6:364-368.
93. PLUMMER ER: Poly(ADP-ribose) polymerase inhibitors: Clinical update. Eur. J. Cancer (2006) 4:141.
94. RATNAM K, LOW JA: Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin. Cancer Res. (2007) 13:1383-1388.
95. WARD JF: The yield of DNA double-strand breaks produced intracellularly by ionizing radiation: a review. Int. J. Radiat. Biol. (1990) 57:1141-1150.
96. BURMA S, CHEN BPC, CHEN DJ: Role of non-homologous end joining (NHEJ) in maintaining genomic integrity. DNA Repair (2006) 5:1042-1048
97. OLIVE P L: The role of DNA single-and double-strand breaks in cell killing by ionizing radiation. Radiat. Res. (1998) 150:S42-S51.
98. ROTHKAMM K, KRUGER I, THOMPSON LH, LOBRICH M: Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol. Cell Biol (2003) 23:5706-5715.
99. SMITH GC, JACKSON SP: The DNA-dcpendent protein kinase. Genes Dev. (1999) 13:916-934.
100. AHNESORG P, SMITH P, JACKSON SP; XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous; end-joining. Cell (2006) 124:301-313.
101. LEES-MILLER SP, MEEK K: Repair of DNA double strand breaks by non-homologous end joining. Biochimie (2003) 85:1161-1173.
102. JEGGO PA, CALDECOTT K, PIDSLEY S, BANKS GR: Sensitivity of Chinese hamster ovary mutants defective in DNA double strand break repair to topoisomerase II inhibitors. Cancer Res. (1989) 49:7057-7063.
103. TANAKA T, YAMAGAMI T, OKA Y, NOMURA T, SUGTYAMA H: The scid mutation in mice causes defects in the repair system for both double-strand DNA breaks and DNA cross-links. Mutat. Res. (1993) 288:277-280.
104. IZZARD RA, JACKSON SP. SMITH GC: Competitive and noncompetitive inhibition of the DNA-dependent protein kinase. Cancer Res. (1999) 59:2581-2586.
105. PRICE BD, YOUMELL MB: The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res. (1996) 56:246-250.
106. BOULTON S, KYLE S, DURKACZ BW: Mechanisms of enhancement of cytotoxicity in etoposide and ionising radiation-treated cells by the protein kinase inhibitor wortmannin. Eur. J. Cancer (2000) 36:535-541.
107. 2-M delay. Clin. Cancer Res. (1997) 3:1149-1156.
108. KRUSZEWSKI M, WOJEWODZKA M, IWANENKO T, SZUMIEL I, OKUYAMA A: Differential inhibitory effect of OK-1035 on DNA repair in L5178Y murine lymphoma sublines with functional or defective repair of double strand breaks. Mutat. Res. (1998) 409:31-36.
109. ISMAIL IH, MARTENSSON S, MOSHINSKY D et al.: SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization. Oncogene (2004) 23:873-882.
110. WILLMORE E, DE CAUX S, SUNTER NJ et al.: A novel DNA-dependent protein kinase inhibitor, NU7026:potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood (2004) 103:4659-4665.
111. HARDCASTLE IR, COCKCROFT X, CURTIN NJ et al.: Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J. Med. Chem. (2005) 48:7829-7846.
112. LEAHY JJ, GOLDING BT, GRIFFIN RJ et al.: Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg. Med. Chem. Lett. (2004) 14:6083-6087.
113. ZHAO Y, THOMAS HD, BATEY MA et al.: Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res. (2006) 66:5354-5362.
114. KASHISHIAN A, DOUANGPANYA H, CLARK D et al.: DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer. Mol. Cancer Ther. (2003) 2:1257-1264.
115. SHINOHARA ET GENG L, TAN J et al.: DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res. (2005) 65:4987-4992.
116. KENNEDY RD, D'ANDREA AD: DNA repair pathways in clinical practice: lessons from paediatric cancer susceptibility syndromes. J. Clin. Oncol. (2006) 24:3799-3808.
117. KAELIN W: The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer (2005) 5:689-698.